Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(54)
•••
Comment by HarveyTwofaceon Apr 25, 2020 3:59am
290 Views
Post# 30952687

RE:RE:RE:RE:RE:RE:RE:RE:Don’t Skin Me Alive MugsMods

RE:RE:RE:RE:RE:RE:RE:RE:Don’t Skin Me Alive MugsModsBoy I do know what I am talking about, me and a couple of doctors and nurses in the family. FYI I've been invested in ATE for three years so whatever nonsense you're trying to fool others with (such as "foregone conclusions" about success in this phase 2b automatically means phase 3 is gonna be a 100% hit....now that's a silly conclusion.) is something you should keep to yourself. Hate to say it but you sound very naive, actually. But you'll learn, just like me and others have. Keep up your "good" work here....... ;-) There are no other motives other than hoping people are more aware about potential risks than you are. Wish everyone luck with their investment, and hope everyone understand different phases means DIFFERENT risks. Nothing here is a given whatever Mr. Fortune Teller is writing. I can say I wish you were right but you're not. And - knowing the risks - I will keep my shares all the way because I don't n e e d the money, I just w a n t them so I will take the risk this time/phase.. .hope everyone else keep their shares too.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities